Annual Report 2024

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2024 151 The United Laboratories International Holdings Limited Annual Report 2024 46. INFORMATION ABOUT THE STATEMENT OF FINANCIAL POSITION OF THE COMPANY (Continued) (b) Reserves Share premium Treasury stock Share-based compensation reserve Retained profits Total RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 At 1 January 2023 3,722,482 – – 1,468,963 5,191,445 Profit and total comprehensive income for the year – – – 173,633 173,633 Dividends recognised as distribution (Note 15) – – – (581,448) (581,448) Recognition of share-based compensation expense – – 6,365 – 6,365 At 31 December 2023 3,722,482 – 6,365 1,061,148 4,789,995 Profit and total comprehensive income for the year – – – 139,492 139,492 Dividends recognised as distribution (Note 15) – – – (1,017,535) (1,017,535) Repurchase of shares – (36,465) – – (36,465) Transaction cost attributable to repurchase of shares – (112) – – (112) Vesting of shares – 35,539 (24,693) (10,846) – Recognition of share-based compensation expense – – 47,364 – 47,364 At 31 December 2024 3,722,482 (1,038) 29,036 172,259 3,922,739 47. EVENT AFTER THE REPORTING PERIOD On 24 March 2025, the Group entered into an exclusive license agreement with an independent third party under which, subject to the terms and conditions thereof, the Group will grant an exclusive license to develop, manufacture, commercialise and exploit a specified product or compounds, which is still at the research and development stage in all countries and territories except for mainland China, Hong Kong, Macau and Taiwan at an upfront payment of US$200 million, together with milestone payments and royalties. The directors of the Company are still in the process of assessing the financial impact of this arrangement.